CD274 and non-small cell lung carcinoma: On the other hand, monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated survival benefits, long lasting responses and good safety profile over chemotherapy in patients with advanced NSCLC in several recent Phase III trials (8–11).